Rheumatology

Litigation, Launch, and Lower Costs: 3 Big Moves in the US Biosimilar Space

August 19th 2025

By Skylar Jeremias

Explore groundbreaking developments in biosimilars, including patent lawsuits, new ustekinumab launches, and innovative access strategies for patients.

Biosimilar Business Recap: Updates on Tocilizumab, Omalizumab, and Ranibizumab Products

August 13th 2025

By Skylar Jeremias

Article

Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ranibizumab.

Japanese Study Provides Postapproval Insights Into Biosimilar Quality Attributes

August 12th 2025

By Skylar Jeremias

Article

Researchers analyze the quality of monoclonal antibody biosimilars in Japan, revealing variations that impact adoption and public confidence in these therapies.

Year-Long Phase 3 Study Confirms Tocilizumab Biosimilar Comparability With Actemra

August 6th 2025

By Skylar Jeremias

Article

CT-P47 emerges as a promising tocilizumab biosimilar, demonstrating comparable efficacy and safety in rheumatoid arthritis treatment, enhancing access and affordability.

Adalimumab Biosimilar Maintains Effectiveness for Patients With Arthritis and Health Care Costs

July 30th 2025

By Cameron Santoro

Article

Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some improvement in ultrasound findings, after switching from original adalimumab to its biosimilar, GP2017.

Data Show Comparable Efficacy, Added Cost Benefit With Adalimumab Biosimilar vs Humira

July 22nd 2025

By Skylar Jeremias

Article

Biosimilar IBI303 offers comparable effectiveness to Humira for ankylosing spondylitis, providing significant cost savings and improved patient retention rates.

Real-World Data Suggest Long-Term Safety of CT-P13 in IBD, RA

July 2nd 2025

By Deana Ferreri, PhD

Article

The MEGA-J study reveals CT-P13's long-term safety and effectiveness in treating inflammatory bowel disease and rheumatoid arthritis, with minimal adverse reactions.

Biosimilars Rheumatology Roundup: June 2025

July 1st 2025

By Skylar Jeremias

Article

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and real-world efficacy insights.

Adalimumab Double Take: The Unexpected Return to Reference Humira

June 30th 2025

By Skylar Jeremias

Article

About 13% of patients who switch from Humira to an adalimumab biosimilar switch back to the originator, according to research from Truveta. However, the presented data may not tell the full story.

Tocilizumab Biosimilar CT-P47 Shows Promise for Rheumatoid Arthritis Self-Administration

June 19th 2025

By Cameron Santoro

Article

Tocilizumab biosimilar CT-P47, administered via autoinjector, offers comparable efficacy and a consistent safety profile to reference tocilizumab in patients with rheumatoid arthritis.